| 摘要 |
FIELD: bioengineering.SUBSTANCE: invention relates to the use of the compound having formulato stabilise a hypoxia induced factor-2 alpha (HIF-2α), for the reduced regulation of phosphoglycerate kinase (PGK) in a cell, and for the increased regulation of the release from the cell of a dissoluble receptor-1 of a vascular endothelial growth factor (sVEGF-1).EFFECT: higher efficiency of the compositions use.13 cl, 15 dwg, 1 tbl, 5 ex |
